Back

Development of low-cost serological immunoassay to detect antiviral antibodies to Sars-Cov-2 Spike protein

Peroni, L.; Toscaro, J.; Canateli, C.; Lima, G.; Pagliarone, a.; Cardoso, E.; Viana, R.; Bassani, J.; Lin-Wang, H.; Abboud, C. S.; Gun, C.; Franchini, K.; Bajgelman, M. C.

2021-06-09 infectious diseases
10.1101/2021.06.07.21258114 medRxiv
Show abstract

Seroconversion to SARS-CoV-2 has been widely studied to evaluate infection spreading for epidemiological purpose, or even in studies of protective immunity in convalescent or vaccinated individuals. The viral particle has an envelope harboring the spike glycoprotein, which can be used as an antigen for assay development, to detect antiviral antibodies to SARS-CoV-2. Since several vaccines encode a spike subunit, the full length spike-based immunoassay should be a universal tool to evaluate seroconversion. In this manuscript, we propose a low-cost ELISA that can be used to detect antiviral IgG to SARS-CoV-2 in human serum.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.